Get started
Author

Elena Vicente Rubio

Observed names: E. Vicente Rubio, Elena Vicente-Rubio, Vicente-Rubio, Elena
OpenAlex ID: A5083171665
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 93
PDF
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
2022 · Javier Salvador Bofill, Fernando Moreno Anton, et al. · The Breast · 6
PDF
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy
2025 · Ayelet Shai, Hans Wildiers, et al. · The Breast · 4
PDF
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain
2026 · Alejandro Falcón-González, Elisenda Llabrés-Valenti, et al. · Frontiers in Oncology · 2
PDF
467P Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
2023 · I. Ceballos Lenza, E. Llabres Valenti, et al. · Annals of Oncology · 2
PDF
Adjuvant radiotherapy for low-risk early breast cancer in elderly women: evidence from randomized trials
2020 · Javier Burgos-Burgos, Beatriz Pinar-Sedeño, et al. · Translational Cancer Research · 2
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
2026 · Tal Sella, Frederieke van Duijnhoven, et al. · The Breast
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy
2026 · Shai, Ayelet, Wildiers, Hans, et al. · CINECA IRIS Institutial Research Information System (University of Genoa)
EE418 Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain
2025 · Ana M. Santaballa, Laura Lema, et al. · Value in Health
Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy
2025 · Ayelet Shai, Hans Wildiers, et al. · SSRN Electronic Journal
Abstract PS3-11: Correlation of pathological complete response and radiological response with Contrast-enhanced mammography in breast cancer patients after neoadjuvant chemotherapy
2021 · Elisenda Llabrés Valentí, Jose Carlos Antela López, et al. · Cancer Research
Hemangioendotelioma epitelial atípico de presentación muscular.
2012 · Y. González González, D. Batista Martin, et al.
Placas eritematoso-violáceas simétricas en un paciente de 65 años de edad
2004 · Elena Vicente Rubio, Isabel Betlloch Mas · Piel
Works count: 13
Citation count: 109
H-index: 3
I10-index: 1
Year
Topic
Type